Kataoka et al., 2024 - Google Patents
Predictors of dropout from abemaciclib therapy in patients with breast cancer: a multicenter retrospective cohort studyKataoka et al., 2024
View PDF- Document ID
- 9003317729609053676
- Author
- Kataoka N
- Hata T
- Hosomi K
- Hirata A
- Ota R
- Nishihara M
- Kimura K
- Iwamoto M
- Ashida A
- Neo M
- Publication year
External Links
Snippet
Objective: This study explored the predictors of dropping out from abemaciclib therapy, a cyclin-dependent kinase 4 and 6 inhibitor, in patients with breast cancer. Material and Methods: Between November 2018 and March 2023, 147 patients with breast cancer treated …
- 229950001573 abemaciclib 0 title abstract description 93
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Frasor et al. | Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome | |
Schummer et al. | Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125 | |
Pernar et al. | A prospective study of the association between physical activity and risk of prostate cancer defined by clinical features and TMPRSS2: ERG | |
Go et al. | Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B‐cell lymphoma | |
Gibbs et al. | Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer | |
EP2245460B1 (en) | Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy | |
Zhang et al. | Prevalence and prognostic value of malnutrition among elderly cancer patients using three scoring systems | |
Luo et al. | PPARα gene is a diagnostic and prognostic biomarker in clear cell renal cell carcinoma by integrated bioinformatics analysis | |
Sato et al. | Predictive value of 3′-deoxy-3′-18F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer | |
Hara et al. | Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma | |
Hoffmann et al. | Increased expression of ido1 is associated with improved survival and increased number of tils in patients with high-grade serous ovarian cancer | |
Kataoka et al. | Predictors of dropout from abemaciclib therapy in patients with breast cancer: a multicenter retrospective cohort study | |
Fatima et al. | Circulatory proteins in women with breast cancer and their chemotherapeutic responses | |
Zheng et al. | Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer | |
Gunawan et al. | The hypoxic response expression as a survival biomarkers in treatment-naive advanced breast cancer | |
Van Mieghem et al. | Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age | |
Kataoka et al. | Predictors of abemaciclib discontinuation in patients with breast cancer: a multicenter retrospective cohort study | |
Nastoupil et al. | P1125: Celestimo: A Phase Iii Trial Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide Versus Rituximab Plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma | |
CN111433375A (en) | Method of selecting a treatment for a cancer patient | |
US20120202888A1 (en) | Biomarkers of prostate cancer and predicting mortality | |
Moffat et al. | KRAS Allelic Variants in Biliary Tract Cancers | |
CN114354931B (en) | Application of splenomegaly in determining curative effect of tumor patient immune checkpoint inhibitor treatment | |
Tutan et al. | Role of systemic immune-inflammation index in predicting mortality in cancer patients in palliative care units | |
Shin et al. | Novel predictive models of early death less than 1 year in patients with metastatic renal cell carcinoma after treatment with first-line tyrosine kinase inhibitors | |
Willis et al. | Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite US study |